Aurobindo Pharma buyback 2026: ₹800 cr at ₹1,475

What the board approved on April 6

Aurobindo Pharma’s board approved a share buyback worth up to ₹800 crore at its meeting on April 6, 2026, as disclosed in a regulatory filing. The company plans to repurchase fully paid-up equity shares with a face value of ₹1 each. The buyback price has been fixed at ₹1,475 per share. The repurchase will be executed through the tender offer route using the stock exchange mechanism. Under a tender offer, eligible shareholders can tender shares at the fixed buyback price, with acceptance typically on a proportionate basis. The buyback is subject to approvals from regulatory and statutory authorities as required under applicable laws. Aurobindo Pharma also constituted a buyback committee to oversee and execute the process.

Offer size and share count

The company intends to buy back up to 54,23,728 equity shares. This quantity represents up to 0.93% of Aurobindo Pharma’s total paid-up equity share capital, as stated in the disclosures. The total consideration is capped at ₹800 crore, excluding transaction costs such as brokerage and taxes. The company’s shares are listed on both BSE and NSE, and the buyback will be conducted in the tender offer category. Axis Capital Limited has been named as the lead manager for the buyback. Aurobindo Pharma noted that the post-buyback shareholding pattern will be determined after completion of the process because the final number of shares tendered and accepted will be known only after the record date.

Key dates investors are tracking

Aurobindo Pharma has fixed April 17, 2026 as the record date to determine shareholder eligibility. As per the details provided, investors holding shares in their demat accounts as of the close on April 16 will be eligible to participate. The tender is expected to open on April 23, 2026 and close on April 29, 2026, with both dates described as tentative in the buyback timeline shared in the synopsis. Separately, some process items such as the “last date to buy shares,” and “finalization of buyback acceptance” were presented with incomplete placeholders in the source table. What is clear is the eligibility cut-off anchored to the April 17 record date and the April 23-29 tender window.

Buyback price and the stated premium

The buyback price of ₹1,475 per share was described as a premium of about 10% to 11.6% over recent closing prices around ₹1,333 to ₹1,335. One data point in the material cited a closing price of ₹1,333.70 as of April 2, 2026. The buyback structure therefore offers shareholders the option to tender shares at a fixed price above those referenced market levels, subject to acceptance ratios and category entitlements. The company also indicated that the buyback price may be increased and the number of shares reduced, subject to regulatory provisions, without changing the overall buyback size.

Retail category: eligibility and entitlement snapshot

The buyback includes a reserved category for small shareholders, with a higher entitlement relative to the general category, as reflected in the entitlement ratios disclosed. For the reserved category for small shareholders, the entitlement ratio was listed as 7/61. For the general category for all other eligible shareholders, the entitlement ratio was listed as 2/249. The synopsis also reiterated the commonly used small-shareholder threshold of maximum market value of holdings up to ₹2,00,000 as on the record date. Using the buyback price of ₹1,475 per share, the illustration computed a maximum of about 135.59 shares, rounded to 136 shares for simplicity. The same illustration used ₹1,333.70 as a reference price (dated April 2, 2026) to estimate an investment value of ₹1,80,840.68 for 136 shares, while noting this figure can change based on the closing price on the record date.

How the tender process works in this case

Participation requires holding Aurobindo Pharma shares as of the record date, April 17, 2026. The synopsis explicitly states that investors should have shares in demat or physical form as on the record date to be eligible. During the tender period, eligible shareholders can tender shares through their broker on BSE or NSE. The buyback is to be carried out on a proportionate basis from all eligible shareholders, including promoters and promoter group members, in line with applicable regulations. The materials also referenced operational steps such as settlement following closure and extinguishment of shares post-buyback, with acceptance depending on category and overall subscription.

What this means for capital allocation

The stated objectives for the buyback include returning surplus funds to shareholders and enhancing overall shareholder returns. The company also cited capital structure optimisation and improvement in financial ratios such as earnings per share and return on equity. Another stated objective is to provide flexibility, allowing shareholders to participate for cash or retain holdings and potentially benefit from increased post-buyback ownership. On the disclosed numbers, the buyback corresponds to 3.93% of the company’s aggregate paid-up equity share capital and free reserves on a standalone basis and 2.62% on a consolidated basis, based on financial statements as at March 2025.

Context: the last buyback and promoter holding

This is described as the company’s first buyback announcement since August 2024. In August 2024, Aurobindo Pharma announced a buyback of 51.36 lakh equity shares at ₹1,460 apiece, with a total outlay of ₹750 crore, also via the tender offer route. In the latest disclosure set, promoters and promoter group entities were reported to hold a 51.82% stake in the company. The current buyback is open to all eligible shareholders, including promoters, on a proportionate basis.

Market reaction and recent price references

Following the April 6 development, the stock gained nearly 2% to an intraday high of ₹1,358 on the NSE, as cited in the synopsis. Another update in the provided material mentioned the stock was down 0.26% to ₹1,332.45 at a point after the announcement. The synopsis also stated the share price gained around 8% over the past month, even as the Nifty 50 declined more than 11% in March. These figures provide the market backdrop against which the buyback premium and investor interest are being discussed.

Key facts at a glance

Timeline investors can follow

Conclusion

Aurobindo Pharma’s ₹800 crore tender-route buyback at ₹1,475 per share sets a clear near-term event window around the April 17 record date and the tentative April 23-29 tender period. The company has outlined objectives tied to capital return and balance-sheet optimisation, while the offer size remains limited to 0.93% of equity. More operational detail is expected through the public announcement and the letter of offer, including the final timetable and process disclosures needed for execution.